补体靶向疗法如何改写神经免疫疾病治疗前景？2026补体日学术交流会倒计时3天，即将开幕！

TL;DR - An AstraZeneca-supported preview of the 2026 Complement Day conference reviews complement-mediated damage in neuroimmune diseases and the therapeutic rationale for C5 inhibition. It highlights generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD), while promoting clinical consensus and broader access to complement-targeted therapies in China.

• Complement activation is reported in over 95% of evaluable AChR-positive gMG patients and can damage the neuromuscular junction through membrane attack complex formation.
• Because even low residual levels of predominantly IgG1/IgG3 AChR antibodies may activate complement, reducing antibodies upstream may not fully prevent tissue injury.
• C5-targeted biologics directly inhibit terminal complement activity, blocking membrane attack complex formation and C5a-mediated inflammation.
• The conference will discuss mechanisms, biomarkers, treatment timing, long-term safety, and individualized responses in gMG and NMOSD; applications in dysferlinopathy and autoimmune encephalitis remain exploratory.